Search：
All Dates：
- All
- 2026-06-11 [Thursday]
- 2026-06-12 [Friday]
- 2026-06-13 [Saturday]
- 2026-06-14 [Sunday]
All Rooms：
- All
- A1-A (102-107)
- A1-A101
- A1-A102
- A1-A103
- A1-A104
- A1-A (105-107)
- A1-A108
- A1-A109
- A1-A110
- A2-A206
- A2-A207
- A2-A208
- A2-A213
- A2-A214
- A2-A215
- B1 Hall (Poster Area)
- B1 Hall (Exhibition Area)
2026-06-11 (Thursday)
A1-A108
14:00-15:05
| Executive Master of Interventional Radiology 1
| NO. | Time | Presentation Topic | Speaker | Affiliation / Organization |
|---|---|---|---|---|
| 1 | 14:00-14:05 |
Opening |
Gao-Jun Teng | Zhongda Hospital, Southeast University, China |
| 2 | 14:05-14:13 |
MRI-based Radiomics Model for Predicting Prognosis in HCC Patients Receiving TACE Combined with Atezolizumab and Bevacizumab |
Qing-Quan Zu | Jiangsu Province Hospital, China |
| 3 | 14:21-14:29 |
precision TACE Combined with Systemic Therapy for Advanced HCC |
Haochen Wang | Peking unniversity first hopital |
| 4 | 14:29-14:37 |
Low-Dose TKI Optimizes TACE-Based Combination Therapy by Targeting Microvasculature and Promoting HEV-Mediated Immune Remodeling in Hepatocellular Carcinoma |
Xue Han | Sun Yat-sen University Cancer Center, China |
| 5 | 14:37-14:45 |
Atezolizumab plus TKIs reduce peritoneal metastasis risk for patients with ruptured HCC receiving TACE/TAE : a multicenter retrospective study |
Fu-An Wang | Jiangsu Subei People's Hospital, China |
| 6 | 14:45-14:53 |
Curative Conversion Resection Following Sequential HAIC, Atezolizumab+Bevacizumab, and Y-90 SIRT for Unresectable Hepatocellular Carcinoma with Hepatic Arterioportal Fistula: A Case Report |
Tuo-Xuan Jin | The First Affiliated Hospital of China Medical University, China |
| 7 | 14:53-15:05 |
Panel Discussion |
Jin Woo Choi | Seoul National University Hospital, ROK(Republic of Korea) |
